Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines

Al B. Benson, Michael I. D’Angelica, Thomas Abrams, Daniel E. Abbott, Aijaz Ahmed, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, David Binder, Mitesh Borad, Christopher Bowlus, Daniel Brown, Adam Burgoyne, Jason Castellanos, Prabhleen Chahal, Jordan Cloyd, Anne M. Covey, Evan S. Glazer, William G. HawkinsRenuka Iyer, Rojymon Jacob, Lawrence Jennings, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Sean Ronnekleiv-Kelly, Vaibhav Sahai, Gagandeep Singh, Stacey Stein, Anita Turk, Jean Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole McMillian, Ryan Schonfeld, Cindy Hochstetler

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.

Original languageEnglish (US)
Pages (from-to)694-704
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume21
Issue number7
DOIs
StatePublished - Jul 2023

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this